Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
AssigneeCoherus Biosciences, Inc.
InventorsChristos Mantzoros, Glenn D. Rosen
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an additional therapeutic agent, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, or a pharmaceutically acceptable salt thereof.
Claims21
1-75. (canceled)
A method of treating non-alcoholic fatty liver disease (NAFLD) in a subject in need thereof comprising administering to the subject
- (a) the compound of Formula (I),
- or a pharmaceutically acceptable salt or solvate thereof, and
- (b) a compound selected from the group consisting of an ASK1 inhibitor, an ACC inhibitor, a caspase inhibitor, a MCR antagonist, a statin, a PCSK9 inhibitor, or a pharmaceutically acceptable salt or solvate of any of the foregoing,
- wherein the amounts of (a) and (b) together are effective in treating NAFLD.
A method of treating fibrosis in a subject in need thereof comprising administering to the subject
- (a) the compound of Formula (I),
- or a pharmaceutically acceptable salt or solvate thereof, and
- (b) a compound selected from the group consisting of an ASK1 inhibitor, an ACC inhibitor, a caspase inhibitor, a MCR antagonist, a statin, a PCSK9 inhibitor, or a pharmaceutically acceptable salt or solvate of any of the foregoing,
- wherein the amounts of (a) and (b) together are effective in treating NAFLD.
A pharmaceutical composition comprising
- (a) the compound of Formula (I),
- or a pharmaceutically acceptable salt or solvate thereof,
- (b) a compound selected from the group consisting of an ASK1 inhibitor, an ACC inhibitor, a caspase inhibitor, a MCR antagonist, a statin, a PCSK9 inhibitor, or a pharmaceutically acceptable salt or solvate of any of the foregoing, and
- one or more pharmaceutical excipients.
Dependencies are inferred from the claim text.